Regarding "antibody cocktail therapy" for mildly ill patients with the new coronavirus, Chugai will expand the target, saying that it has newly confirmed the effect of reducing the risk of developing the disease in asymptomatic patients by about 30%. I applied to the Ministry of Health, Labor and Welfare.
The antibody cocktail therapy, in which two types of antibodies are administered by intravenous drip at the same time, is intended for patients with mild to moderate illness and who are at risk of becoming severe, and by the 5th of this month, a total of about 35,000 people will be administered nationwide. Is believed to have received.
Chugai Pharmaceutical Co., Ltd., which has marketing rights in Japan, announced on the 11th that it has been confirmed to reduce the risk of developing the disease by 31% as a result of administration to asymptomatic patients in previous overseas clinical trials.
In addition, when administered to people who became close contacts at home for the purpose of preventing infection, the risk of developing infection was reduced by 81% in people who were not infected at the time of starting the clinical trial. is.
Based on these results, Chugai has applied to the Ministry of Health, Labor and Welfare to newly approve its administration to asymptomatic patients and its use as a preventive drug.